| Literature DB >> 20468699 |
Abstract
In new, previously untreated tuberculosis patients preference is given to treatment with major antituberculous drugs, namely Isoniazid, PAS and Streptomycin. The exchange of PAS with one of the recently introduced drugs (Rifampin, Ethambutol) should await the results of the therapeutic trials being conducted at various centers. In the meantime, these new drugs should be reserved for reactivation cases, for individuals hypersensitive to major antituberculous agents, or who are not responding satisfactorily to the routine therapy and for patients infected with organisms resistant to Isoniazid, PAS or Streptomycin.Entities:
Year: 1971 PMID: 20468699 PMCID: PMC2370273
Source DB: PubMed Journal: Can Fam Physician ISSN: 0008-350X Impact factor: 3.275